Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma()

BACKGROUND: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death globally. Mechanistic target of rapamycin (mTOR) is frequently up-regulated in HCC and plays an important role in HCC tumorigenesis. Tumors with loss of tuberous sclerosis complex 2 (TSC2), a negative regulator of...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Jinhyun, Lee, Jeeyun, Kim, Jusun, Kim, Seung Tae, Lee, Sujin, Kim, Sun Young, Ha, Sang Yun, Park, Cheol-Keun, Lim, Ho Yeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2016
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067924/
https://www.ncbi.nlm.nih.gov/pubmed/27751352
http://dx.doi.org/10.1016/j.tranon.2016.08.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067924/
https://www.ncbi.nlm.nih.gov/pubmed/27751352
http://dx.doi.org/10.1016/j.tranon.2016.08.009

Ejemplares similares